Stephen D. Simpson

After months of rumors, a major pharmaceutical company makes a firm offer for this hot rare disease specialist

Pfizer has moved to establish a good preclinical presence in a promising emerging cancer therapy class

Roche faces significant competition and threats from generic manufacturers, but has a comfortable cushion to support its dividend

Amgen's pipeline may not have huge mega-blockbusters, but there are some promising drugs worth watching

Medtronic's eye-popping deal for Covidien is a great move for a company looking to the long-term future of healthcare

Apple and Google are both making inroads into the healthcare arena.

Medtronic's Analyst Day was very thorough, though not really full of game-changing revelations

Merck's deal for Idenix is all about establishing long-term viability in the emerging HCV space

Although it doesn't offer a bargain bin price, Zoetis offers a very strong business in an attractive industry

A bid for Smith & Nephew may not be sexy, but it would be smart.

Valeant's new and improved offer isn't that new, or that much improved.

A strong Tecfidera launch, rising expectations for the hemophilia franchise, and a pipeline rich in high-potential drugs has kept this biotech off the rocks as the sector tosses around

A focus on scale and returns should be good news to JNJ shareholders.

Surprisingly good results from a heart failure drug don't completely shift the story for this Swiss drug giant

Three recent developments help Boston Scientific, but don't fundamentally alter the thesis

Medtronic has seen several setbacks, but the underlying free cash flow still supports a higher stock price.

Pfizer tries again to make a deal for AstraZeneca, but the target won't budge.

Multiple abstracts support growing investor enthusiasm for Big Pharma's immuno-oncology efforts.

In less than 48 hours, investors have seen significant updates on five pharmaceutical M&A deals.

Alnylam continues to add candidates to its clinical pipeline